CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Biora Therapeutics Inc. - BIOR CFD

    1.3212
    7.31%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.0376
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026235 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026235%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.004012 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.004012%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 0.01
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Biora Therapeutics Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 1.2312
    Open* 1.4412
    1-Year Change* 496.52%
    Day's Range* 1.2512 - 1.4412
    52 wk Range 1.26-7.68
    Average Volume (10 days) 284.10K
    Average Volume (3 months) 3.62M
    Market Cap 31.53M
    P/E Ratio -100.00K
    Shares Outstanding 23.70M
    Revenue 18.00K
    EPS -9.56
    Dividend (Yield %) N/A
    Beta 1.00
    Next Earnings Date Mar 28, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 1, 2023 1.3212 -0.0600 -4.34% 1.3812 1.4612 1.2312
    Nov 30, 2023 1.2312 0.0400 3.36% 1.1912 1.2612 1.1912
    Nov 29, 2023 1.2012 -0.1000 -7.69% 1.3012 1.3012 1.1612
    Nov 28, 2023 1.2912 -0.0700 -5.14% 1.3612 1.3612 1.2912
    Nov 27, 2023 1.3612 0.0400 3.03% 1.3212 1.3712 1.3212
    Nov 24, 2023 1.3312 -0.0300 -2.20% 1.3612 1.3612 1.3312
    Nov 22, 2023 1.3512 0.0200 1.50% 1.3312 1.3512 1.3112
    Nov 21, 2023 1.3212 -0.0400 -2.94% 1.3612 1.3712 1.3212
    Nov 20, 2023 1.3212 -0.0300 -2.22% 1.3512 1.3612 1.2912
    Nov 17, 2023 1.3512 0.0700 5.46% 1.2812 1.3512 1.2712
    Nov 16, 2023 1.2812 -0.0700 -5.18% 1.3512 1.3512 1.2412
    Nov 15, 2023 1.3312 -0.0300 -2.20% 1.3612 1.3812 1.2612
    Nov 14, 2023 1.3212 -0.0400 -2.94% 1.3612 1.4912 1.2412
    Nov 13, 2023 1.3412 -0.1000 -6.94% 1.4412 1.4412 1.3012
    Nov 10, 2023 1.4112 -0.0500 -3.42% 1.4612 1.4812 1.3612
    Nov 9, 2023 1.4812 -0.0900 -5.73% 1.5712 1.6112 1.4612
    Nov 8, 2023 1.5512 -0.1400 -8.28% 1.6912 1.7112 1.5412
    Nov 7, 2023 1.6612 -0.0500 -2.92% 1.7112 1.8312 1.6012
    Nov 6, 2023 1.7012 -0.1900 -10.05% 1.8912 1.9112 1.6912
    Nov 3, 2023 1.8712 -0.0600 -3.11% 1.9312 1.9712 1.8412

    Biora Therapeutics Inc. Events

    Time (UTC) Country Event
    Thursday, March 28, 2024

    Time (UTC)

    20:00

    Country

    US

    Event

    Q4 2023 Biora Therapeutics Inc Earnings Release
    Q4 2023 Biora Therapeutics Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 0.305 1.247 0.162 143.985 127.974
    Revenue 0.305 1.247 0.162 143.985 127.974
    Cost of Revenue, Total 0 0 100.492 92.076
    Gross Profit 1.247 0.162 43.493 35.898
    Total Operating Expense 63.686 119.984 118.981 284.104 242.213
    Selling/General/Admin. Expenses, Total 38.037 73.299 60.038 120.212 101.425
    Research & Development 24.049 45.785 47.743 63.4 48.712
    Operating Income -63.381 -118.737 -118.819 -140.119 -114.239
    Interest Income (Expense), Net Non-Operating 15.614 -66.793 -9.915 -9.199 -11.418
    Other, Net -1.483 6.89 -13.884 0.575 1.801
    Net Income Before Taxes -49.25 -178.64 -142.618 -148.743 -123.856
    Net Income After Taxes -48.83 -178.521 -105.086 -148.037 -129.106
    Net Income Before Extra. Items -48.83 -178.521 -105.086 -148.037 -129.106
    Net Income -38.157 -247.412 -192.528 -148.037 -129.106
    Total Adjustments to Net Income 0 -0.268 -80.79 0
    Income Available to Common Excl. Extra. Items -48.83 -178.521 -105.354 -228.827 -129.106
    Income Available to Common Incl. Extra. Items -38.157 -247.412 -192.796 -228.827 -129.106
    Diluted Net Income -38.157 -247.412 -192.796 -228.827 -129.106
    Diluted Weighted Average Shares 7.63511 3.84619 1.10052 1.80655 1.80655
    Diluted EPS Excluding Extraordinary Items -6.39546 -46.4151 -95.7315 -126.665 -71.4654
    Dividends per Share - Common Stock Primary Issue 0 0
    Diluted Normalized EPS -6.21668 -46.263 -89.1165 -126.665 -71.4654
    Unusual Expense (Income) 1.6 0.9 11.2
    Total Extraordinary Items 10.673 -68.891 -87.442
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0.002 0.002 0.014 0.08 0.104
    Revenue 0.002 0.002 0.014 0.08 0.104
    Cost of Revenue, Total
    Gross Profit
    Total Operating Expense 14.936 15.546 13.79 13.967 14.314
    Selling/General/Admin. Expenses, Total 8.953 8.356 8.023 8.147 8.41
    Research & Development 5.983 7.19 5.767 5.82 5.904
    Operating Income -14.934 -15.544 -13.776 -13.887 -14.21
    Interest Income (Expense), Net Non-Operating -2.864 -1.816 2.773 -0.729 7.341
    Other, Net -0.005 -0.081 -2.207 -0.1 0.035
    Net Income Before Taxes -17.803 -17.441 -13.21 -14.716 -6.834
    Net Income After Taxes -17.807 -17.441 -13.469 -14.874 -5.997
    Net Income Before Extra. Items -17.807 -17.441 -13.469 -14.874 -5.997
    Total Extraordinary Items 0 0 -0.253 9.76 0.484
    Net Income -17.807 -17.441 -13.722 -5.114 -5.513
    Total Adjustments to Net Income
    Income Available to Common Excl. Extra. Items -17.807 -17.441 -13.469 -14.874 -5.997
    Income Available to Common Incl. Extra. Items -17.807 -17.441 -13.722 -5.114 -5.513
    Diluted Net Income -17.807 -17.441 -13.722 -5.114 -5.513
    Diluted Weighted Average Shares 12.1431 10.9706 8.3577 7.47815 7.37487
    Diluted EPS Excluding Extraordinary Items -1.46643 -1.5898 -1.61157 -1.98899 -0.81317
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -1.46643 -1.5898 -1.61157 -1.98899 -0.81317
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 38.116 98.775 126.338 74.648 88.946
    Cash and Short Term Investments 30.486 88.397 92.076 33.042 69.205
    Cash & Equivalents 30.486 88.397 92.076 33.042 49.005
    Short Term Investments 0 20.2
    Total Receivables, Net 0.828 0.653 6.634 22.823 8.146
    Accounts Receivable - Trade, Net 0 0.653 6.634 22.189 1.952
    Total Inventory 10.937 7.616
    Prepaid Expenses 3.634 6.123 8.521 6.476 3.375
    Other Current Assets, Total 3.168 3.602 19.107 1.37 0.604
    Total Assets 53.525 108.839 154.44 101.727 116.397
    Property/Plant/Equipment, Total - Net 3.136 3.666 8.106 15.891 15.339
    Property/Plant/Equipment, Total - Gross 7.135 9.287 13.894 33.201 29.455
    Accumulated Depreciation, Total -3.999 -5.621 -5.788 -17.31 -14.116
    Goodwill, Net 6.072 6.072 6.072 6.219 6.219
    Intangibles, Net 4.771 5.699
    Other Long Term Assets, Total 0.201 0.326 13.924 0.198 0.194
    Total Current Liabilities 23.305 61.609 72.67 100.337 78.057
    Accounts Payable 3.606 8.709 17.379 15.754 11.035
    Accrued Expenses 14.064 30.847 50.312 77.571 61.019
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 0 0.012 0.338 0.968 1.229
    Other Current Liabilities, Total 5.635 22.041 4.641 6.044 4.774
    Total Liabilities 155.812 193.815 261.434 185.601 153.365
    Total Long Term Debt 127.811 126.392 160.203 72.405 71.508
    Long Term Debt 127.811 126.392 160.161 72.047 70.615
    Capital Lease Obligations 0.042 0.358 0.893
    Other Liabilities, Total 4.696 5.814 28.561 12.859 3.8
    Total Equity -102.287 -84.976 -106.994 -83.874 -36.968
    Preferred Stock - Non Redeemable, Net 0.106 0.02
    Common Stock 0.008 0.006 0.059 0.052 0.05
    Additional Paid-In Capital 743.626 722.782 452.992 283.217 124.202
    Retained Earnings (Accumulated Deficit) -826.843 -788.686 -541.274 -348.478 -142.469
    Treasury Stock - Common -19.078 -19.078 -18.771 -18.771 -18.771
    Total Liabilities & Shareholders’ Equity 53.525 108.839 154.44 101.727 116.397
    Total Common Shares Outstanding 8.9285 7.27489 2.23089 1.80655 1.80655
    Long Term Investments 6 0
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 19.247 33.885 37.168 38.116 46.36
    Cash and Short Term Investments 12.569 26.452 30.463 30.486 37.06
    Cash & Equivalents 12.569 26.452 30.463 30.486 37.06
    Total Receivables, Net 0.818 0.819 0.828 0.828 0.828
    Accounts Receivable - Trade, Net 0 0
    Total Inventory
    Prepaid Expenses 3.179 3.912 3.059 3.634 5.461
    Other Current Assets, Total 2.681 2.702 2.818 3.168 3.011
    Total Assets 34.703 49.673 53.243 53.525 62.614
    Property/Plant/Equipment, Total - Net 3.07 3.238 3.744 3.136 3.955
    Property/Plant/Equipment, Total - Gross 5.474 5.637 6.036 7.135 7.944
    Accumulated Depreciation, Total -2.404 -2.399 -2.292 -3.999 -3.989
    Goodwill, Net 6.072 6.072 6.072 6.072 6.072
    Intangibles, Net
    Other Long Term Assets, Total 0.314 0.478 0.259 0.201 0.227
    Total Current Liabilities 69.544 37.668 25.083 23.305 27.391
    Accounts Payable 3.905 5.042 3.422 3.606 2.356
    Accrued Expenses 21.124 21.271 16.333 14.064 19.543
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 0 0
    Other Current Liabilities, Total 44.515 11.355 5.328 5.635 5.492
    Total Liabilities 153.489 170.554 158.241 155.812 160.057
    Total Long Term Debt 80.378 128.568 128.185 127.811 127.445
    Long Term Debt 80.378 128.568 128.185 127.811 127.445
    Capital Lease Obligations
    Other Liabilities, Total 3.567 4.318 4.973 4.696 5.221
    Total Equity -118.786 -120.881 -104.998 -102.287 -97.443
    Common Stock 0.021 0.011 0.011 0.008 0.153
    Additional Paid-In Capital 835.817 760.277 758.353 743.626 734.607
    Retained Earnings (Accumulated Deficit) -935.545 -862.091 -844.284 -826.843 -813.121
    Treasury Stock - Common -19.079 -19.078 -19.078 -19.078 -19.082
    Total Liabilities & Shareholders’ Equity 34.703 49.673 53.243 53.525 62.614
    Total Common Shares Outstanding 23.411 13.4209 11.859 8.9285 7.56389
    Long Term Investments 6 6 6 6 6
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -38.157 -247.412 -192.528 -148.037 -129.106
    Cash From Operating Activities -64.417 -167.486 -165.744 -106.124 -65.126
    Cash From Operating Activities 0.907 1.437 5.059 6.349 6.073
    Deferred Taxes 0 6.245
    Non-Cash Items -22.517 104.353 72.895 2.91 5.501
    Cash Taxes Paid 0.031 0.367 0.062 0.006 0.211
    Cash Interest Paid 5.871 7.536 3.927 7.529 7.618
    Changes in Working Capital -4.65 -25.864 -51.17 32.654 46.161
    Cash From Investing Activities -0.792 -1.242 -4.944 16.525 55.831
    Capital Expenditures -0.792 -0.855 -4.944 -3.725 -4.832
    Other Investing Cash Flow Items, Total 0 -0.387 0 20.25 60.663
    Cash From Financing Activities 7.298 165.049 229.722 73.636 -12.807
    Financing Cash Flow Items -5.12 -5.532 -6.745 -4.679 -0.25
    Issuance (Retirement) of Stock, Net 12.43 172.224 137.742 79.59 -10.807
    Issuance (Retirement) of Debt, Net -0.012 -1.643 98.725 -1.275 -1.75
    Net Change in Cash -57.911 -3.679 59.034 -15.963 -22.102
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -17.441 -38.157 -24.435 -19.321 -13.808
    Cash From Operating Activities -12.098 -64.417 -53.399 -43.594 -23.955
    Cash From Operating Activities 0.147 0.907 0.749 0.547 0.322
    Non-Cash Items 2.003 -22.517 -22.436 -13.221 -5.045
    Cash Taxes Paid 0 0.031 0.018 0.017 0.001
    Cash Interest Paid 5.871 4.811 4.811 0
    Changes in Working Capital 3.193 -4.65 -7.277 -11.599 -5.424
    Cash From Investing Activities -0.006 -0.792 -0.72 -0.556 -0.342
    Capital Expenditures -0.016 -0.792 -0.72 -0.556 -0.342
    Cash From Financing Activities 12.081 7.298 2.782 4.259 3.134
    Financing Cash Flow Items -0.802 -5.12 -3.748 -0.612 -0.48
    Issuance (Retirement) of Stock, Net 12.883 12.43 6.542 4.883 3.626
    Issuance (Retirement) of Debt, Net 0 -0.012 -0.012 -0.012 -0.012
    Net Change in Cash -0.023 -57.911 -51.337 -39.891 -21.163
    Other Investing Cash Flow Items, Total 0.01 0 0 0 0
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Athyrium Capital Management, LP Investment Advisor/Hedge Fund 88.9445 12348838 10654357 2023-09-18 HIGH
    Mohanty (Aditya P) Individual Investor 4.7573 660498 441569 2023-08-15 HIGH
    Anson Funds Management LP. Hedge Fund 4.4449 617126 617126 2023-06-30 LOW
    Sabby Management, LLC Investment Advisor/Hedge Fund 3.4761 482609 482609 2023-06-30 HIGH
    d'Esparbes (Eric) Individual Investor 1.9968 277227 179628 2023-08-15 HIGH
    Neumann (Clarke William) Individual Investor 1.9023 264110 173992 2023-08-15 HIGH
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 1.7606 244442 3825 2023-06-30 LOW
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.5821 80812 36720 2023-06-30 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 0.4685 65051 0 2023-06-30 LOW
    Schonfeld Strategic Advisors LLC Hedge Fund 0.2939 40800 -1700 2023-06-30 HIGH
    GSA Capital Partners LLP Hedge Fund 0.2767 38415 -19086 2023-06-30 HIGH
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.2382 33073 15500 2023-06-30 LOW
    Creative Planning, Inc. Investment Advisor/Hedge Fund 0.1585 22000 1000 2023-06-30 LOW
    LPL Financial LLC Investment Advisor 0.1569 21784 1066 2023-06-30 LOW
    Bridgeway Capital Management, LLC Investment Advisor 0.1245 17280 0 2023-06-30 MED
    Susquehanna International Group, LLP Investment Advisor 0.1229 17060 6227 2023-06-30 MED
    Alter (Jeffrey D) Individual Investor 0.1095 15200 12500 2023-06-14 LOW
    CIBC Asset Management Inc. Investment Advisor 0.1088 15110 0 2023-09-30 LOW
    Powell (Lynne M) Individual Investor 0.1037 14400 12500 2023-06-14 HIGH
    Kotzin (Brian L) Individual Investor 0.1033 14347 12500 2023-06-14 LOW

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Biora Therapeutics Inc. Company profile

    Progenity (PROG)/Biora Therapeutics (BIOR) is a biotechnology firm focused on the development of oral biotherapeutics. Founded in 2010, the company creates drug-device combinations that enable new therapeutic delivery methods in two main areas:

    • Targeted delivery of therapeutics to the site of disease in the gastrointestinal (GI) tract, to improve outcomes for patients with Inflammatory Bowel Disease (IBD)

    • Systemic biotherapeutic delivery, which is intended to replace injection with needle-free, oral delivery technology

    Progenity is also working on diagnostic tools to help characterise the GI tract and diagnose GI diseases such as Small Intestine Bacterial Overgrowth (SIBO). The technologies can pinpoint the location of the disease.

    Prior to June 2021, the San Diego, California-based company focused on the prenatal carrier screening and non-invasive prenatal test market. It targeted preconception planning and routine pregnancy management for genetic disease risk assessment.

    The company’s operations included anatomic and molecular pathology testing products under an affiliate, Avero Diagnostics.

    A former affiliate, Mattison Pathology, a Texas firm trading as Avero Diagnostics, expanded the company’s operations to include anatomic and molecular pathology testing products.

    The company also operated a certified laboratory in Michigan that specialised in the molecular testing markets serving women’s health providers in the obstetric, gynaecological, fertility, and maternal foetal medicine speciality areas in the US.

    In June 2021, Progenity announced a strategic transformation which included closing the Progenity genetics lab in Ann Arbor, Michigan. It sold the Avero laboratory business in December 2021 as part of the transformation. 

    On 12 April 2022, Progenity announced it would change its name to Biora Therapeuctics in the second quarter of 2022. The strategy aims to better reflect its focus of developing targeted and systemic oral delivery of biotherapeutics.

    The company will also change its stock symbol on the Nasdaq from PROG to BIOR.  Progenity went public on 19 June 2020. 

    Industry: Bio Therapeutic Drugs

    4330 La Jolla Village Drive
    Suite 200
    SAN DIEGO
    CALIFORNIA 92122
    US

    Income Statement

    • Annual
    • Quarterly

    News

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023
    GBP

    UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?

    UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.

    10:48, 21 November 2023

    People also watch

    Gold

    2,072.25 Price
    +1.760% 1D Chg, %
    Long position overnight fee -0.0193%
    Short position overnight fee 0.0111%
    Overnight fee time 22:00 (UTC)
    Spread 0.30

    XRP/USD

    0.63 Price
    -0.250% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    Oil - Crude

    74.50 Price
    -1.560% 1D Chg, %
    Long position overnight fee -0.0136%
    Short position overnight fee -0.0083%
    Overnight fee time 22:00 (UTC)
    Spread 0.040

    BTC/USD

    39,645.70 Price
    +0.010% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading